Biodesix reported second quarter 2026 financial results with total revenue of $26.9 million, a 34% increase year-over-year, driven by a 42% rise in Diagnostic Testing revenue to $25.4 million and a 38% growth in test volumes to 20,900. The company achieved an 82% gross margin and reported a net loss of $7.3 million, a 37% improvement from the prior year period. Adjusted EBITDA improved by 56%, narrowing the loss to $3.2 million. Biodesix maintained its full-year 2026 revenue guidance between $108 million and $114 million. The company holds $30.0 million in cash and cash equivalents, which includes $6.5 million from an at-the-market equity program.